Literature DB >> 28208200

Massive Pulmonary Embolism: Extracorporeal Membrane Oxygenation and Surgical Pulmonary Embolectomy.

Aaron Weinberg1, Victor F Tapson2, Danny Ramzy3.   

Abstract

Massive pulmonary embolism (PE) refers to large emboli that cause hemodynamic instability, right ventricular failure, and circulatory collapse. According to the 2016 ACCP Antithrombotic Guidelines, therapy for massive PE should include systemic thrombolytic therapy in conjunction with anticoagulation and supportive care. However, in patients with a contraindication to systemic thrombolytics or in those who fail the above interventions, extracorporeal membrane oxygenation (ECMO) and/or surgical embolectomy may be used to improve oxygenation, achieve hemodynamic stability, and successfully treat massive PE. Randomized controlled human trials evaluating ECMO in this context have not been done, and its role has not been well-defined. The European Society of Cardiology 2014 acute PE guidelines briefly mention that ECMO can be used for massive PE as a method for hemodynamic support and as an adjunct to surgical embolectomy. The 2016 CHEST Antithrombotic Therapy for venous thromboembolism Disease guidelines do not mention ECMO in the management of massive PE. However, multiple case reports and small series cited benefit with ECMO for massive PE. Further, ECMO may facilitate stabilization for surgical embolectomy. Unfortunately, ECMO requires full anticoagulation to maintain the functionality of the system; hence, significant bleeding complicates its use in 35% of patients. Contraindications to ECMO include high bleeding risk, recent surgery or hemorrhagic stroke, poor baseline functional status, advanced age, neurologic dysfunction, morbid obesity, unrecoverable condition, renal failure, and prolonged cardiopulmonary resuscitation without adequate perfusion of end organs. In this review, we discuss management of massive PE, with an emphasis on the potential role for ECMO and/or surgical embolectomy. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28208200     DOI: 10.1055/s-0036-1597559

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  7 in total

Review 1.  The Role and Impact of Extracorporeal Membrane Oxygenation in Critical Care.

Authors:  Iqbal Ratnani; Divina Tuazon; Asma Zainab; Faisal Uddin
Journal:  Methodist Debakey Cardiovasc J       Date:  2018 Apr-Jun

Review 2.  Principles and indications of extracorporeal life support in general thoracic surgery.

Authors:  Karen McRae; Marc de Perrot
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

3.  In-Hospital Outcome in Patients Underwent Extracorporeal Membrane Oxygenation in Life-Threatening High-Risk Pulmonary Embolism.

Authors:  Jung Hyun Choi; Sang Yeub Lee; Yong Hyun Park; Jae-Hyeong Park; Kye Hun Kim
Journal:  Int J Heart Fail       Date:  2020-05-27

Review 4.  Extracorporeal Membrane Oxygenation (ECMO) and the Critical Cardiac Patient.

Authors:  David A Baran
Journal:  Curr Transplant Rep       Date:  2017-07-10

5.  Post traumatic inferior vena cava thrombosis: A case report and review of literature.

Authors:  Amine Chakroun; Mohamed Said Nakhli; Mohamed Kahloul; Mohamed Amine Harrathi; Walid Naija
Journal:  Int J Surg Case Rep       Date:  2017-05-15

Review 6.  Overview of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiogenic Shock.

Authors:  Adamantios Tsangaris; Tamas Alexy; Rajat Kalra; Marinos Kosmopoulos; Andrea Elliott; Jason A Bartos; Demetris Yannopoulos
Journal:  Front Cardiovasc Med       Date:  2021-07-07

Review 7.  Venoarterial Extracorporeal Membrane Oxygenation for Acute Massive Pulmonary Embolism: a Meta-Analysis and Call to Action.

Authors:  Elona Rrapo Kaso; Jonathan A Pan; Michael Salerno; Alexandra Kadl; Chad Aldridge; Ziv J Haskal; Jamie L W Kennedy; Sula Mazimba; Andrew D Mihalek; Nicholas R Teman; Jay Giri; Herbert D Aronow; Aditya M Sharma
Journal:  J Cardiovasc Transl Res       Date:  2021-07-19       Impact factor: 3.216

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.